CD73-generated adenosine: Orchestrating the tumor-stroma interplay to promote cancer growth

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Allard, Bertrand ^a   Turcotte, Martin ^a   Stagg, John ^a  

^a Institut du Cancer de Montreal   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; ADENOSINE; ADENOSINE RECEPTOR; CYTOKINE;

AUTOCRINE EFFECT; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL PROLIFERATION; ENDOTHELIUM CELL; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNE RESPONSE GENE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; METASTASIS; NONHUMAN; PARACRINE SIGNALING; POINT MUTATION; PROMOTER REGION; REGULATORY T LYMPHOCYTE; REVIEW; SYSTEMATIC REVIEW (TOPIC); TUMOR CELL; ANIMAL; ENZYMOLOGY; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; STROMA CELL;

5'-NUCLEOTIDASE; ADENOSINE; ANIMALS; CELL PROLIFERATION; HUMANS; NEOPLASMS; STROMAL CELLS; T-LYMPHOCYTES, REGULATORY;

EID: 84869039651     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/485156     Document Type: Review

References (84)

1. Mellman I., Coukos G., Dranoff G., Cancer immunotherapy comes of age. Nature 2011 480 7378 480 489 10.1038/nature10673
2. Galon J., Pagès F., Marincola F. M., The immune score as a new possible approach for the classification of cancer. Journal of Translational Medicine 2012 10, article 1
3. Mlecnik B., Tosolini M., Kirilovsky A., Berger A., Bindea G., Meatchi T., Bruneval P., Trajanoski Z., Fridman W. H., Pagès F., Galon J., Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. Journal of Clinical Oncology 2011 29 6 610 618 2-s2.0-79952093380 10.1200/JCO.2010.30.5425
4. Galluzzi L., Senovilla L., Zitvogel L., Kroemer G., The secret ally: immunostimulation by anticancer drugs. Nature Reviews Drug Discovery 2012 11 3 215 233 10.1038/nrd3626
5. Ma Y., Aymeric L., Locher C., Mattarollo S. R., Delahaye N. F., Pereira P., Boucontet L., Apetoh L., Ghiringhelli F., Casares N., Lasarte J. J., Matsuzaki G., Ikuta K., Ryffel B., Benlagha K., Tesnière A., Ibrahim N., Déchanet-Merville J., Chaput N., Smyth M. J., Kroemer G., Zitvogel L., Contribution of IL-17-producing γδ T cells to the efficacy of anticancer chemotherapy. Journal of Experimental Medicine 2011 208 3 491 503 2-s2.0-79952716229 10.1084/jem.20100269
6. Stagg J., Loi S., Divisekera U., Ngiow S. F., Duret H., Yagita H., Teng M. W., Smyth M. J., Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proceedings of the National Academy of Sciences of the United States of America 2011 108 17 7142 7147 2-s2.0-79955570584 10.1073/pnas.1016569108
7. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J. F., Testori A., Grob J. J., Davidson N., Richards J., Maio M., Hauschild A., Miller W. H., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T. T., Humphrey R., Hoos A., Wolchok J. D., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. New England Journal of Medicine 2011 364 26 2517 2526 2-s2.0-79959772576 10.1056/NEJMoa1104621
8. Topalian S. L., Hodi F. S., Brahmer J. R., Gettinger S. N., Smith D. C., McDermott D. F., Powderly J. D., Carvajal R. D., Sosman J. A., Atkins M. B., Leming P. D., Spigel D. R., Antonia S. J., Horn L., Drake C. G., Pardoll D. M., Chen L., Sharfman W. H., Anders R. A., Taube J. M., McMiller T. L., Xu H., Korman A. J., Jure-Kunkel M., Agrawal S., McDonald D., Kollia G. D., Gupta A., Wigginton J. M., Sznol M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine 2012 366 26 2443 2454 10.1056/NEJMoa1200690
9. Brahmer J. R., Tykodi S. S., Chow L. Q. M., Hwu W.-J., Topalian S. L., Hwu P., Drake C. G., Camacho L. H., Kauh J., Odunsi K., Pitot H. C., Hamid O., Bhatia S., Martins R., Eaton K., Chen S., Salay T. M., Alaparthy S., Grosso J. F., Korman A. J., Parker S. M., Agrawal S., Goldberg S. M., Pardoll D. M., Gupta A., Wigginton J. M., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New England Journal of Medicine 2012 366 26 2455 2465 10.1056/NEJMoa1200694
10. Stagg J., Smyth M. J., Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010 29 39 5346 5358 2-s2.0-77957564570 10.1038/onc.2010.292
11. Shirley D. G., Vekaria R. M., Sévigny J., Ectonucleotidases in the kidney. Purinergic Signalling 2009 5 4 501 511 2-s2.0-70949089945 10.1007/s11302-009-9152-4
12. Henttinen T., Jalkanen S., Yegutkin G. G., Adherent leukocytes prevent adenosine formation and impair endothelial barrier function by ecto- 5 ′ -nucleotidase/CD73-dependent mechanism. Journal of Biological Chemistry 2003 278 27 24888 24895 2-s2.0-0043092170 10.1074/jbc.M300779200 (Pubitemid 37548648)
13. Eckle T., Krahn T., Grenz A., Köhler D., Mittelbronn M., Ledent C., Jacobson M. A., Osswald H., Thompson L. F., Unertl K., Eltzschig H. K., Cardioprotection by ecto- 5 ′ -nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007 115 12 1581 1590 2-s2.0-34247343418 10.1161/CIRCULATIONAHA.106.669697 (Pubitemid 46648643)
14. Elliott M. R., Chekeni F. B., Trampont P. C., Lazarowski E. R., Kadl A., Walk S. F., Park D., Woodson R. I., Ostankovich M., Sharma P., Lysiak J. J., Harden T. K., Leitinger N., Ravichandran K. S., Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009 461 7261 282 286 2-s2.0-70249090374 10.1038/nature08296
15. Zitvogel L., Kepp O., Galluzzi L., Kroemer G., Inflammasomes in carcinogenesis and anticancer immune responses. Nature Immunology 2012 13 4 343 351 10.1038/ni.2224
16. Fredholm B. B., IJzerman A. P., Jacobson K. A., Linden J., Müller C. E., International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptorsan update. Pharmacological Reviews 2011 63 1 1 34 2-s2.0-79952033865 10.1124/pr.110.003285
17. Serra S., Horenstein A. L., Vaisitti T., Brusa D., Rossi D., Laurenti L., D'Arena G., Coscia M., Tripodo C., Inghirami G., Robson S. C., Gaidano G., Malavasi F., Deaglio S., CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 2011 118 23 6141 6152 10.1182/blood-2011-08-374728
18. Bavaresco L., Bernardi A., Braganhol E., Cappellari A. R., Rockenbach L., Farias P. F., Wink M. R., Delgado-Caedo A., Battastini A. M. O., The role of ecto- 5 ′ nucleotidase/CD73 in glioma cell line proliferation. Molecular and Cellular Biochemistry 2008 319 1-2 61 68 2-s2.0-55649124110 10.1007/s11010-008-9877-3
19. Sadej R., Spychala J., Skladanowski A. C., Expression of ecto- 5 ′ -nucleotidase (eN, CD73) in cell lines from various stages of human melanoma. Melanoma Research 2006 16 3 213 222 2-s2.0-33746116078 10.1097/01.cmr. 0000215030.69823.11 (Pubitemid 44085095)
20. Spychala J., Lazarowski E., Ostapkowicz A., Ayscue L. H., Jin A., Mitchell B. S., Role of estrogen receptor in the regulation of ecto- 5 ′ -nucleotidase and adenosine in breast cancer. Clinical Cancer Research 2004 10 2 708 717 2-s2.0-0842311602 10.1158/1078-0432.CCR-0811-03 (Pubitemid 38174010)
21. Haas M. J., CD73: double-breasted suit, SciBX: Science-Business eXchange 3. 2010
22. Synnestvedt K., Furuta G. T., Comerford K. M., Louis N., Karhausen J., Eltzschig H. K., Hansen K. R., Thompson L. F., Colgan S. P., Ecto- 5 ′ -nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. Journal of Clinical Investigation 2002 110 7 993 1002 2-s2.0-0036771775 10.1172/JCI200215337
23. Li X., Zhou T., Zhi X., Zhao F., Yin L., Zhou P., Effect of hypoxia/reoxygenation on CD73 (ecto- 5 ′ -nucleotidase) in mouse microvessel endothelial cell lines. Microvascular Research 2006 72 1-2 48 53 2-s2.0-33746336981 10.1016/j.mvr.2006.04.005 (Pubitemid 44118391)
24. Semenza G. L., Hypoxia-inducible factor 1: regulator of mitochondrial metabolism and mediator of ischemic preconditioning. Biochimica et Biophysica Acta 2011 1813 7 1263 1268 2-s2.0-79957952535 10.1016/j.bbamcr.2010.08.006
25. Eltzschig H. K., Ibla J. C., Furuta G. T., Leonard M. O., Jacobson K. A., Enjyoji K., Robson S. C., Colgan S. R., Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endotheliumml: role of ectonucleotidases and adenosine A 2B receptors. Journal of Experimental Medicine 2003 198 5 783 796 2-s2.0-0042386007 10.1084/jem.20030891 (Pubitemid 37087777)
26. Eltzschig H. K., Kö hler D., Eckle T., Kong T., Robson S. C., Colgan S. P., Central role of Sp1-regulated CD39 in hypoxia/ischemia protection. Blood 2009 113 1 224 232 2-s2.0-59449096105 10.1182/blood-2008-06-165746
27. Spychala J., Zimmermann A. G., Mitchell B. S., Tissue-specific regulation of the ecto- 5 ′ -nucleotidase promoter. Role of the cAMP response element site in mediating repression by the upstream regulatory region. Journal of Biological Chemistry 1999 274 32 22705 22712 2-s2.0-0033529680 10.1074/jbc.274.32.22705 (Pubitemid 29379318)
28. Spychala J., Kitajewski J., Wnt and β -catenin signaling target the expression of ecto- 5 ′ -nucleotidase and increase extracellular adenosine generation. Experimental Cell Research 2004 296 2 99 108 10.1016/j.yexcr.2003. 11.001 (Pubitemid 38624632)
29. Polakis P., Wnt signaling and cancer. Genes and Development 2000 14 15 1837 1851 2-s2.0-0033895709 (Pubitemid 30639518)
30. Wang H., Lee S., Lo Nigro C., Lattanzio L., Merlano M., Monteverde M., Matin R., Purdie K., Mladkova N., Bergamaschi D., Harwood C., Syed N., Szlosarek P., Briasoulis E., McHugh A., Thompson A., Evans A., Leigh I., Fleming C., Inman G. J., Hatzimichael E., Proby C., Crook T., NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity. British Journal of Cancer 2012 106 8 1446 1452 10.1038/bjc.2012.95
31. Beavis P. A., Stagg J., Darcy P. K., Smyth M. J., CD73: a potent suppressor of antitumor immune responses. Trends in Immunology 2012 33 5 231 237 10.1016/j.it.2012.02.009
32. Wu X.-R., He X.-S., Chen Y.-F., High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. Journal of Surgical Oncology 2012 106 2 130 137
33. Leth-Larsen R., Lund R., Hansen H. V., Laenkholm A. V., Tarin D., Jensen O. N., Ditzel H. J., Metastasis-related plasma membrane proteins of human breast cancer cells identified by comparative quantitative mass spectrometry. Molecular and Cellular Proteomics 2009 8 6 1436 1449 2-s2.0-67049095042 10.1074/mcp.M800061-MCP200
34. Supernat A., Markiewicz A., Seroczyska B., Skokowski J., Sejda A., Szade J., Czapiewski P., Biernat W., Zaczek A., CD73 expression as a potential marker of good prognosis in breast carcinoma. Applied Immunohistochemistry and Molecular Morphology 2012 20 2 103 107 10.1097/PAI.0b013e3182311d82
35. Deaglio S., Dwyer K. M., Gao W., Friedman D., Usheva A., Erat A., Chen J. F., Enjyoji K., Linden J., Oukka M., Kuchroo V. K., Strom T. B., Robson S. C., Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. Journal of Experimental Medicine 2007 204 6 1257 1265 2-s2.0-34250351459 10.1084/jem.20062512 (Pubitemid 46919862)
36. Regateiro F. S., Howie D., Nolan K. F., Agorogiannis E. I., Greaves D. R., Cobbold S. P., Waldmann H., Generation of anti-inflammatory adenosine byleukocytes is regulated by TGF- β European Journal of Immunology 2011 41 10 2955 2965 10.1002/eji.201141512
37. Borsellino G., Kleinewietfeld M., Di Mitri D., Sternjak A., Diamantini A., Giometto R., Höpner S., Centonze D., Bernardi G., Dell'Acqua M. L., Rossini P. M., Battistini L., Rötzschke O., Falk K., Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007 110 4 1225 1232 2-s2.0-34547098277 10.1182/blood-2006-12-064527 (Pubitemid 47281420)
38. Mandapathil M., Hilldorfer B., Szczepanski M. J., Czystowska M., Szajnik M., Ren J., Lang S., Jackson E. K., Gorelik E., Whiteside T. L., Generation and accumulation of immunosuppressive adenosine by human CD4+CD25 high FOXP3+ regulatory T Cells. Journal of Biological Chemistry 2010 285 10 7176 7186 2-s2.0-77951234655 10.1074/jbc.M109.047423
39. Hilchey S. P., Kobie J. J., Cochran M. R., Secor-Socha S., Wang J. C. E., Hyrien O., Burack W. R., Mosmann T. R., Quataert S. A., Bernstein S. H., Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness. Journal of Immunology 2009 183 10 6157 6166 2-s2.0-77954229218 10.4049/jimmunol.0900475
40. Dwyer K. M., Hanidziar D., Putheti P., Hill P. A., Pommey S., McRae J. L., Winterhalter A., Doherty G., Deaglio S., Koulmanda M., Gao W., Robson S. C., Strom T. B., Expression of CD39 by human peripheral blood CD4+CD25+ T cells denotes a regulatory memory phenotype. American Journal of Transplantation 2010 10 11 2410 2420 2-s2.0-78349232055 10.1111/j.1600-6143.2010.03291.x
41. Romio M., Reinbeck B., Bongardt S., Hüls S., Burghoff S., Schrader J., Extracellular purine metabolism and signaling of CD73-derived adenosine in murine treg and teff cells. American Journal of Physiology 2011 301 2 C530 C539 2-s2.0-79961008951 10.1152/ajpcell.00385.2010
42. Chalmin F., Mignot G., Bruchard M., Chevriaux A., Végran F., Hichami A., Ladoire S., Derangère V., Vincent J., Masson D., Robson S. C., Eberl G., Pallandre J., Borg C., Ryffel B., Apetoh L., Rébé C., Ghiringhelli F., Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012 36 3 362 373 10.1016/j.immuni.2011.12.019
43. Zarek P. E., Huang C. T., Lutz E. R., Kowalski J., Horton M. R., Linden J., Drake C. G., Powell J. D., A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 2008 111 1 251 259 2-s2.0-38049141544 10.1182/blood-2007-03-081646
44. Stagg J., Divisekera U., Duret H., Sparwasser T., Teng M. W. L., Darcy P. K., Smyth M. J., CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Research 2011 71 8 2892 2900 2-s2.0-79954576658 10.1158/0008-5472.CAN-10-4246
45. Wang L., Fan J., Thompson L. F., Zhang Y., Shin T., Curiel T. J., Zhang B., CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. Journal of Clinical Investigation 2011 121 6 2371 2382 2-s2.0-79957921286 10.1172/JCI45559
46. Yegutkin G. G., Marttila-Ichihara F., Karikoski M., Niemelä J., Laurila J. P., Elima K., Jalkanen S., Salmi M., Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. European Journal of Immunology 2011 41 5 1231 1241 2-s2.0-79955153842 10.1002/eji.201041292
47. Mandapathil M., Szczepanski M. J., Szajnik M., Ren J., Lenzner D. E., Jackson E. K., Gorelik E., Lang S., Johnson J. T., Whiteside T. L., Increased ectonucleotidase expression and activity in regulatory T cells of patients with head and neck cancer. Clinical Cancer Research 2009 15 20 6348 6357 2-s2.0-70350231926 10.1158/1078-0432.CCR-09-1143
48. Mandapathil M., Szczepanski M. J., Szajnik M., Ren J., Jackson E. K., Johnson J. T., Gorelik E., Lang S., Whiteside T. L., Adenosine and prostaglandin e2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. Journal of Biological Chemistry 2010 285 36 27571 27580 2-s2.0-77956254094 10.1074/jbc.M110.127100
49. Jalkanen S., Salmi M., VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 1 18 26 2-s2.0-37549031262 10.1161/ATVBAHA.107.153130
50. Ålgars A., Karikoski M., Yegutkin G. G., Stoitzner P., Niemelä J., Salmi M., Jalkanen S., Different role of CD73 in leukocyte trafficking via blood and lymph vessels. Blood 2011 117 16 4387 4393 2-s2.0-79955944679 10.1182/blood-2010-11-321646
51. Takedachi M., Qu D., Ebisuno Y., Oohara H., Joachims M. L., McGee S. T., Maeda E., McEver R. P., Tanaka T., Miyasaka M., Murakami S., Krahn T., Blackburn M. R., Thompson L. F., CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes. Journal of Immunology 2008 180 9 6288 6296 2-s2.0-44449146084
52. Zernecke A., Bidzhekov K., Özüyaman B., Fraemohs L., Liehn E. A., Lüscher-Firzlaff J. M., Lüscher B., Schrader J., Weber C., CD73/Ecto- 5 ′ -nucleotidase protects against vascular inflammation and neointima formation. Circulation 2006 113 17 2120 2127 2-s2.0-33646456788 10.1161/CIRCULATIONAHA.105.595249
53. Mills J. H., Thompson L. F., Mueller C., Waickman A. T., Jalkanen S., Niemela J., Airas L., Bynoe M. S., CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America 2008 105 27 9325 9330 2-s2.0-48249097173 10.1073/pnas. 0711175105
54. Hilaire C. S., Shira C., Ziegler S. G., Markello T. C., Brusco A., Groden C., Gill F., Carlson-Donohoe H., Lederman R. J., Chen M. Y., Yang D., Siegenthaler M. P., Arduino C., Mancini C., Freudenthal B., Stanescu H. C., Zdebik A. A., Chaganti R. K., Nussbaum R. L., Kleta R., Gahl W. A., Boehm M., NT5E mutations and arterial calcifications. New England Journal of Medicine 2011 364 5 432 442 2-s2.0-79551565257 10.1056/NEJMoa0912923
55. Eltzschig H. K., Thompson L. F., Karhausen J., Cotta R. J., Ibla J. C., Robson S. C., Colgan S. P., Endogenous adenosine produced during hypoxia attenuates neutrophil accumulation: coordination by extracellular nucleotide metabolism. Blood 2004 104 13 3986 3992 2-s2.0-10244222236 10.1182/blood-2004- 06-2066 (Pubitemid 39620148)
56. Lennon P. F., Taylor C. T., Stahl G. L., Colgan S. P., Neutrophil-derived 5'-adenosine monophosphate promotes endothelial barrier function via CD73-mediated conversion to adenosine and endothelial A(2B) receptor activation. Journal of Experimental Medicine 1998 188 8 1433 1443 2-s2.0-0032547817 10.1084/jem.188.8.1433 (Pubitemid 28489580)
57. Kong T., Westerman K. A., Faigle M., Eltzschig H. K., Colgan S. P., HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB Journal 2006 20 13 2242 2250 2-s2.0-33845604971 10.1096/fj.06-6419com (Pubitemid 44953854)
58. Ryzhov S., McCaleb J. L., Goldstein A. E., Biaggioni I., Feoktistov I., Role of adenosine receptors in the regulation of angiogenic factors and neovascularization in hypoxia. Journal of Pharmacology and Experimental Therapeutics 2007 320 2 565 572 2-s2.0-33846407222 10.1124/jpet.106.114850 (Pubitemid 46147935)
59. Feoktistov I., Goldstein A. E., Ryzhov S., Zeng D., Belardinelli L., Voyno-Yasenetskaya T., Biaggioni I., Differential expression of adenosine receptors in human endothelial cells: role of A2B receptors in angiogenic factor regulation. Circulation Research 2002 90 5 531 538 2-s2.0-0037155773 10.1161/01.RES.0000012203.21416.14 (Pubitemid 34640902)
60. Ahmad A., Ahmad S., Glover L., Miller S. M., Shannon J. M., Guo X., Franklin W. A., Bridges J. P., Schaack J. B., Colgan S. P., White C. W., Adenosine A2A receptor is a unique angiogenic target of HIF-2 α in pulmonary endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 2009 106 26 10684 10689 2-s2.0-67649804934 10.1073/pnas.0901326106
61. Desai A., Victor-Vega C., Gadangi S., Montesinos M. C., Chu C. C., Cronstein B. N., Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1. Molecular Pharmacology 2005 67 5 1406 1413 2-s2.0-17844388561 10.1124/mol.104.007807 (Pubitemid 40594139)
62. Umapathy N. S., Fan Z., Zemskov E. A., Alieva I. B., Black S. M., Verin A. D., Molecular mechanisms involved in adenosine-induced endothelial cell barrier enhancement. Vascular Pharmacology 2010 52 5-6 199 206 2-s2.0-77950917821 10.1016/j.vph.2009.12.008
63. Narravula S., Lennon P. F., Mueller B. U., Colgan S. P., Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function. Journal of Immunology 2000 165 9 5262 5268 2-s2.0-0034327277
64. Niemelä J., Henttinen T., Yegutkin G. G., Airas L., Kujari A. M., Rajala P., Jalkanen S., IFN- α induced adenosine production on the endotheliumml: a mechanism mediated by CD73 (ecto- 5 ′ -nucleotidase) up-regulation. Journal of Immunology 2004 172 3 1646 1653 2-s2.0-1642444080 (Pubitemid 38116812)
65. Niemelä J., Ifergan I., Yegutkin G. G., Jalkanen S., Prat A., Airas L., IFN- β regulates CD73 and adenosine expression at the blood-brain barrier. European Journal of Immunology 2008 38 10 2718 2726 2-s2.0-58149250587 10.1002/eji.200838437
66. Khoa N. D., Montesinos M. C., Williams A. J., Kelly M., Cronstein B. N., Th1 cytokines regulate adenosine receptors and their downstream signaling elements in human microvascular endothelial cells. Journal of Immunology 2003 171 8 3991 3998 2-s2.0-0141923779 (Pubitemid 37238673)
67. Kalsi K., Lawson C., Dominguez M., Taylor P., Yacoub M. H., Smolenski R. T., Regulation of ecto- 5 ′ -nucleotidase by TNF- α in human endothelial cells. Molecular and Cellular Biochemistry 2002 232 1-2 113 119 2-s2.0-0036010756 10.1023/A:1014806916844 (Pubitemid 34413887)
68. Airas L., Niemela J., Jalkanen S., CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism. Journal of Immunology 2000 165 10 5411 5417 2-s2.0-0034669958
69. Airas L., Niemelä J., Salmi M., Puurunen T., Smith D. J., Jalkanen S., Differential regulation and function of CD73, a glycosyl- phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells. Journal of Cell Biology 1997 136 2 421 431 2-s2.0-0031047221 10.1083/jcb.136.2.421 (Pubitemid 27063091)
70. Sethi N., Kang Y., Unravelling the complexity of metastasismolecular understanding and targeted therapies. Nature Reviews Cancer 2011 11 10 735 748 10.1038/nrc3125
71. Lee H., Lin E. C. K., Liu L., Smith J. W., Gene expression profiling of tumor xenografts: in vivo analysis of organ-specific metastasis. International Journal of Cancer 2003 107 4 528 534 2-s2.0-0142117238 10.1002/ijc.11428 (Pubitemid 37296111)
72. Stagg J., Beavis P. A., Divisekera U., Liu M. C. P., Möller A., Darcy P. K., Smyth M. J., CD73-deficient mice are resistant to carcinogenesis. Cancer Research 2012 72 9 2190 2196 10.1158/0008-5472.CAN-12-0420
73. Stagg J., Divisekera U., McLaughlin N., Sharkey J., Pommey S., Denoyer D., Dwyer K. M., Smyth M. J., Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America 2010 107 4 1547 1552 2-s2.0-75949112218 10.1073/pnas.0908801107
74. Richard C. L., Tan E. Y., Blay J., Adenosine upregulates CXCR4 and enhances the proliferative and migratory responses of human carcinoma cells to CXCL12/SDF-1 α International Journal of Cancer 2006 119 9 2044 2053 2-s2.0-33748861607 10.1002/ijc.22084 (Pubitemid 44423660)
75. Woodhouse E. C., Amanatullah D. F., Schetz J. A., Liotta L. A., Stracke M. L., Clair T., Adenosine receptor mediates motility in human melanoma cells. Biochemical and Biophysical Research Communications 1998 246 3 888 894 2-s2.0-0032577223 10.1006/bbrc.1998.8714 (Pubitemid 28420953)
76. Zhou P., Zhi X., Zhou T., Chen S., Li X., Wang L., Yin L., Shao Z., Ou Z., Overexpression of ecto- 5 ′ -nucleotidase (CD73) promotes T-47D human breast cancer cells invasion and adhesion to extracellular matrix. Cancer Biology and Therapy 2007 6 3 426 431 2-s2.0-34548255860 (Pubitemid 47328312)
77. Wang L., Zhou X., Zhou T., Ma D., Chen S., Zhi X., Yin L., Shao Z., Ou Z., Zhou P., Ecto- 5 ′ -nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. Journal of Cancer Research and Clinical Oncology 2008 134 3 365 372 2-s2.0-38649133357 10.1007/s00432-007-0292-z (Pubitemid 351170058)
78. Zhi X., Chen S., Zhou P., Shao Z., Wang L., Ou Z., Yin L., RNA interference of ecto- 5 ′ -nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clinical and Experimental Metastasis 2007 24 6 439 448 2-s2.0-34548435229 10.1007/s10585-007-9081-y (Pubitemid 47367686)
79. Künzli B. M., Bernlochner M. I., Rath S., Käser S., Csizmadia E., Enjyoji K., Cowan P., d'Apice A., Dwyer K., Rosenberg R., Perren A., Friess H., Maurer C. A., Robson S. C., Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signalling 2011 7 2 231 241 2-s2.0-79961011452 10.1007/s11302-011-9228-9
80. Ohta A., Gorelik E., Prasad S. J., Ronchese F., Lukashev D., Wong M. K. K., Huang X., Caldwell S., Liu K., Smith P., Chen J. F., Jackson E. K., Apasov S., Abrams S., Sitkovsky M., A2A adenosine receptor protects tumors from antitumor T cells. Proceedings of the National Academy of Sciences of the United States of America 2006 103 35 13132 13137 2-s2.0-33748357735 10.1073/pnas.0605251103 (Pubitemid 44338928)
81. Jin D., Fan J., Wang L., Thompson L. F., Liu A., Daniel B. J., Shin T., Curiel T. J., Zhang B., CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Research 2010 70 6 2245 2255 2-s2.0-77950231071 10.1158/0008-5472.CAN-09-3109
82. Zhou X., Zhi X., Zhou P., Chen S., Zhao F., Shao Z., Ou Z., Yin L., Effects of ecto- 5 ′ -nucleotidase on human breast cancer cell growth in vitro and in vivo. Oncology Reports 2007 17 6 1341 1346 2-s2.0-34548008177
83. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y., Ortiz C., Vermaelen K., Panaretakis T., Mignot G., Ullrich E., Perfettini J. L., Schlemmer F., Tasdemir E., Uhl M., Génin P., Civas A., Ryffel B., Kanellopoulos J., Tschopp J., André F., Lidereau R., McLaughlin N. M., Haynes N. M., Smyth M. J., Kroemer G., Zitvogel L., Activation of the NLRP3 inflammasome in dendritic cells induces IL-1 β -dependent adaptive immunity against tumors. Nature Medicine 2009 15 10 1170 1178 2-s2.0-70350569295 10.1038/nm.2028
84. Aymeric L., Apetoh L., Ghiringhelli F., Tesniere A., Martins I., Kroemer G., Smyth M. J., Zitvogel L., Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Research 2010 70 3 855 858 2-s2.0-76249128304 10.1158/0008-5472.CAN-09-3566